Recombinant Human alpha-Galactosidase A/GLA Protein, CF
Recombinant Human alpha-Galactosidase A/GLA Protein, CF Summary
Product Specifications
Met1-Leu429, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
6146-GH
| Formulation | Supplied as a 0.2 μm filtered solution in Tris and NaCl. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 50 mM Sodium Citrate, 50 mM NaCl, pH 4.0
- Recombinant Human alpha ‑Galactosidase A/GLA (rhGLA) (Catalog # 6146-GH)
- Substrate: 4-methylumbelliferyl-alpha -D-galactopyranoside (Sigma, Catalog # M7633), 6.7 mM Stock in DMSO
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Dilute rhGLA to 4.0 ng/µL in Assay Buffer.
- Dilute Substrate to 800 µM in Assay Buffer.
- Load into plate 50 µL of 4.0 ng/µL rhGLA, and start the reaction by adding 50 µL of 800 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL Substrate.
- Read at excitation and emission wavelengths of 365 nm and 445 nm, respectively, in kinetic mode for 5 minutes.
- Calculate the specific activity:
|
Specific Activity (pmol/min/µg) = |
Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) |
| amount of enzyme (µg) |
*Adjusted for Substrate Blank
**Derived using calibration standard 4-Methylumbelliferone (Sigma, Catalog # M1381).
- rhGLA: 0.200 µg
- Substrate: 400 µM
Scientific Data
View Larger
Recombinant Human alpha-Galactosidase A/GLA Protein, CF (Catalog # 6146-GH) hydrolyses the terminal alpha -galactosyl moieties from glycolipids and glycoproteins. The common ceramide trihexoside substrate is displayed in the diagram.
View Larger
Recombinant Human alpha-Galactosidase A/GLA Protein, CF (Catalog # 6146-GH) is measured by its ability to hydrolyze 4-methylumbelliferyl-alpha -D-galactopyranoside.
View Larger
2 μg/lane of Recombinant Human alpha ‑Galactosidase A/GLA Protein (Catalog # 6146-GH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45-55 kDa.
Reconstitution Calculator
Background: alpha-Galactosidase A/GLA
Human alpha -Galactosidase A is a homodimeric glycoprotein that can release terminal alpha -galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose (1). It is a lysosomal enzyme and is responsible for degradation of glycolipid globotriaosylceramide (Gb3) (Gal alpha 1‑4Gal beta 1‑4Glc beta ‑ceramide). Mutations in this gene cause Fabry disease, an X-linked hereditary lysosomal storage disease with the accumulation of Gb3 in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes (2, 3). Inability to prevent the glycosphingolipid deposition can cause hypertension, strokes, heart attack and progressive renal failure (4). Current treatment for Fabry disease is enzyme replacement therapy using intravenously delivered recombinant alpha -Galactosidase A (5, 6).
-
Ioannou, Y.A. et al. (1998) Biochem. J. 332:789.
-
Koide, T. et al. (1990) FEBS Lett. 259:353.
-
Ioannou Y.A, et al. (1992) J. Cell Biol. 119:1137.
-
Germain, D.P. (2002) Expert. Opin. Investig. Drugs. 11:1467.
-
Barngrover, D. (2003) J. Biotechnol. 95:280.
-
Mignani, R. and Cagnoli, L. (2004) J. Nephrol. 17:354.
Citations for Recombinant Human alpha-Galactosidase A/GLA Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
Authors: M Deng, H Zhou, Z Liang, Z Li, Y Wang, W Guo, AY Zhao, F Li, Y Mu, AZ Zhao
Biomolecules, 2022-12-27;13(1):.
Species: N/A
Sample Types: Recombinant Protein
Applications: Western Blot Control -
Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates
Authors: S Cecioni, RA Ashmus, PA Gilormini, S Zhu, X Chen, X Shan, C Gros, MC Deen, Y Wang, R Britton, DJ Vocadlo
Nature Chemical Biology, 2022-02-24;18(3):332-341.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The New Pharmacological Chaperones PBXs Increase alpha-Galactosidase A Activity in Fabry Disease Cellular Models
Authors: P Besada, M Gallardo-G, T Pérez-Márq, L Patiño-Álv, S Pantano, C Silva-Lópe, C Terán, A Arévalo-Gó, A Ruz-Zafra, J Fernández-, S Ortolano
Biomolecules, 2021-12-10;11(12):.
Species: Human
Sample Types: Protein
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human alpha-Galactosidase A/GLA Protein, CF
Average Rating: 5 (Based on 2 Reviews)
Have you used Recombinant Human alpha-Galactosidase A/GLA Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
